Phaseline

Companies › Shenzhen Xinhe Biomedical

Shenzhen Xinhe Biomedical: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology; next expected readout Oct 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XH001 Injection
Personalized mRNA neoantigen cancer vaccine
–Phase 1Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer); Gastrointestinal Cancer; Advanced Gastric CancerOct 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07329894XH001 InjectionPhase 1Gastrointestinal CancerOncologyAug 2027
NCT07298200XH001 InjectionPhase 1Advanced Gastric CancerOncologyJun 2028
NCT07594964XH001 InjectionPhase 1Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer)OncologyOct 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.